A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity

Abstract Intravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations. Thus, there are concerns about systemic com...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yong Cheng, Qingyu Meng, Dandan Linghu, Mingwei Zhao, Jianhong Liang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2a6976448096415bb298f7741443f4aa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2a6976448096415bb298f7741443f4aa
record_format	dspace
spelling	oai:doaj.org-article:2a6976448096415bb298f7741443f4aa2021-12-02T15:08:28ZA lower dose of intravitreal conbercept effectively treats retinopathy of prematurity10.1038/s41598-018-28987-62045-2322https://doaj.org/article/2a6976448096415bb298f7741443f4aa2018-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-28987-6https://doaj.org/toc/2045-2322Abstract Intravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations. Thus, there are concerns about systemic complications, in these premature infants who are developing vital organ systems. This study is to determine whether a low dosage (0.15 mg/0.015 mL) of IVC is effective in the treatment of Zone II Stage 2/3 + ROP. A total of 38 eyes of 20 infants were analyzed retrospectively. We identified treatment effectiveness as complete regression of retinopathy and retinal vascularisation to zone III. The mean gestational age (GA), postmenstrual age (PMA) at treatment and birth weights (BW) were 28.6 ± 2.2 weeks, 39.3 ± 3.0 weeks and 1297.5 ± 429.2 g respectively. Primary effectiveness (react to IVC 0.15 mg alone) was found in 32/38 eyes (84.2%). Secondary effectiveness (a second IVC was required) was found in 6/38 eyes (15.8%). Follow-up continued until 90 weeks’ postmenstrual age and showed no recurrences of plus disease or neovascularization. The study suggests 0.15 mg IVC is effective for Zone II Stage 2/3 + ROP, and there is no adverse ocular outcomes during the follow-up period.Yong ChengQingyu MengDandan LinghuMingwei ZhaoJianhong LiangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-6 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yong Cheng Qingyu Meng Dandan Linghu Mingwei Zhao Jianhong Liang A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
description	Abstract Intravitreal Conbercept (IVC) is the latest applied and effective treatment for the management of retinopathy of prematurity (ROP). However, conbercept escapes from the vitreous into the general circulation and reduce systemic VEGF concentrations. Thus, there are concerns about systemic complications, in these premature infants who are developing vital organ systems. This study is to determine whether a low dosage (0.15 mg/0.015 mL) of IVC is effective in the treatment of Zone II Stage 2/3 + ROP. A total of 38 eyes of 20 infants were analyzed retrospectively. We identified treatment effectiveness as complete regression of retinopathy and retinal vascularisation to zone III. The mean gestational age (GA), postmenstrual age (PMA) at treatment and birth weights (BW) were 28.6 ± 2.2 weeks, 39.3 ± 3.0 weeks and 1297.5 ± 429.2 g respectively. Primary effectiveness (react to IVC 0.15 mg alone) was found in 32/38 eyes (84.2%). Secondary effectiveness (a second IVC was required) was found in 6/38 eyes (15.8%). Follow-up continued until 90 weeks’ postmenstrual age and showed no recurrences of plus disease or neovascularization. The study suggests 0.15 mg IVC is effective for Zone II Stage 2/3 + ROP, and there is no adverse ocular outcomes during the follow-up period.
format	article
author	Yong Cheng Qingyu Meng Dandan Linghu Mingwei Zhao Jianhong Liang
author_facet	Yong Cheng Qingyu Meng Dandan Linghu Mingwei Zhao Jianhong Liang
author_sort	Yong Cheng
title	A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
title_short	A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
title_full	A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
title_fullStr	A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
title_full_unstemmed	A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
title_sort	lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/2a6976448096415bb298f7741443f4aa
work_keys_str_mv	AT yongcheng alowerdoseofintravitrealconbercepteffectivelytreatsretinopathyofprematurity AT qingyumeng alowerdoseofintravitrealconbercepteffectivelytreatsretinopathyofprematurity AT dandanlinghu alowerdoseofintravitrealconbercepteffectivelytreatsretinopathyofprematurity AT mingweizhao alowerdoseofintravitrealconbercepteffectivelytreatsretinopathyofprematurity AT jianhongliang alowerdoseofintravitrealconbercepteffectivelytreatsretinopathyofprematurity AT yongcheng lowerdoseofintravitrealconbercepteffectivelytreatsretinopathyofprematurity AT qingyumeng lowerdoseofintravitrealconbercepteffectivelytreatsretinopathyofprematurity AT dandanlinghu lowerdoseofintravitrealconbercepteffectivelytreatsretinopathyofprematurity AT mingweizhao lowerdoseofintravitrealconbercepteffectivelytreatsretinopathyofprematurity AT jianhongliang lowerdoseofintravitrealconbercepteffectivelytreatsretinopathyofprematurity
_version_	1718388112506224640

A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity

Ejemplares similares